Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Percentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions.
| Analyst | Firm | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| Chris Schott | JPMorgan | 10 questions · 10% challenging |
| Larry Biegelsen | Wells Fargo | 8 questions · 13% challenging |
| Alex Hammond | Wolfe Research | 8 questions · 0% challenging |
| Asad Haider | Goldman Sachs | 8 questions · 0% challenging |
| Terence Flynn | Morgan Stanley | 8 questions · 13% challenging |
| Vamil Divan | Guggenheim | 7 questions · 14% challenging |
| Joanne Wuensch | Citigroup | 6 questions · 17% challenging |
| Shagun Singh | RBC Capital Markets | 5 questions · 20% challenging |
| Danielle Antalffy | UBS | 4 questions · 25% challenging |
| Jayson Bedford | Raymond James | 4 questions · 25% challenging |
| Firm | Analysts | Questions · challengingPercentage of questions scored as challenging — where the analyst pushed back, pressed for specifics, or questioned management's assumptions. |
|---|---|---|
| JPMorgan | 1 analyst | 10 questions · 10% challenging |
| Goldman Sachs | 2 analysts | 9 questions · 0% challenging |
| Wolfe Research | 1 analyst | 8 questions · 0% challenging |
| Morgan Stanley | 1 analyst | 8 questions · 13% challenging |
| Wells Fargo | 1 analyst | 8 questions · 13% challenging |
| Guggenheim | 1 analyst | 7 questions · 14% challenging |
| UBS | 2 analysts | 6 questions · 17% challenging |
| Citigroup | 1 analyst | 6 questions · 17% challenging |
On August 4, 2026, the company announced that Jennifer Taubert will retire from her position as Executive Vice President, Worldwide Chairman, Innovative Medicine and as a member of the Executive Committee, effective September 1, 2026. A related press release was attached as Exhibit 99.1.
What each event means for JNJ’s sentiment score is part of Tellvest Pro.
Johnson & Johnson delivered a Q2 2026 beat, with worldwide sales of $25.3 billion up 5.6% operationally and management raising full-year operational sales guidance by $400 million to a 6.5%-7.1% range. Growth was led by Innovative Medicine, up 6.8%, where DARZALEX grew 17.6% to more than $4 billion and TREMFYA surged 71% to its first $2 billion quarter on IBD momentum, more than offsetting a 55.7% STELARA decline from biosimilar competition. GAAP diluted EPS was $2.27 versus $2.29 a year ago, weighed down by higher litigation, restructuring, and orthopedic-separation charges below the operating line, while adjusted operational EPS rose 4.7% to $2.90. MedTech was the soft spot, growing 3.6% as cardiovascular decelerated to 3.1% on Abiomed weakness following a neutral U.K. high-risk PCI trial and a China EP inventory headwind. Management lifted its full-year adjusted operational EPS range to $11.50-$11.65 and reiterated a path to more than $100 billion in annual revenue and double-digit growth by the end of the decade.
Revenue Growth | Product Launch | Innovation & R&D | Competitive Dynamics | Demand | Capital Allocation | Regulation Policy | Guidance Reliability | |
|---|---|---|---|---|---|---|---|---|
| 2024Q4 | 3 | 1 | 1 | 1 | 1 | 1 | ||
| 2025Q1 | 3 | 1 | 1 | 3 | 1 | 1 | ||
| 2025Q2 | 5 | 3 | 3 | 1 | 1 | |||
| 2025Q3 | 5 | 2 | 2 | 2 | 4 | 1 | 2 | |
| 2025Q4 | 3 | 1 | 4 | 2 | 2 | 3 | 1 | |
| 2026Q1 | 2 | 7 | 3 | 5 | 6 | 1 | ||
| 2026Q2 | 3 | 6 | 2 | 1 | 4 | 1 |
| '24Q4 | '25Q1 | '25Q2 | '25Q3 | '25Q4 | '26Q1 | '26Q2 | |
|---|---|---|---|---|---|---|---|
| Revenue Growth | 3 | 3 | 5 | 5 | 3 | 2 | 3 |
| Product Launch | 1 | 1 | 3 | 2 | 1 | 7 | 6 |
| Innovation & R&D | 1 | 1 | 3 | 2 | 4 | 3 | 2 |
| Competitive Dynamics | 1 | 3 | 1 | 2 | 2 | 5 | 1 |
| Demand | 1 | 6 | 4 | ||||
| Capital Allocation | 1 | 4 | 2 | ||||
| Regulation Policy | 1 | 1 | 1 | 3 | |||
| Guidance Reliability | 1 | 2 | 1 | 1 | 1 |
The table scrolls sideways. Swipe it, or select it and use the arrow keys.
| Quarter | Revenue | Rev YoY | EPS | EPS YoY | Gross margin | Op margin | Net margin | FCF |
|---|---|---|---|---|---|---|---|---|
| FY2024 Q4 | $22.52B | +5.3% | $1.41 | -15.6% | 68.3% | 17.1% | 15.2% | $4.84B |
| FY2025 Q1 | $21.89B | +2.4% | $4.54 | +238.8% | 66.4% | 28.8% | 50.2% | $3.38B |
| FY2025 Q2 | $23.74B | +5.8% | $2.29 | +18.7% | 67.9% | 28.7% | 23.3% | $2.48B |
| FY2025 Q3 | $23.99B | +6.8% | $2.12 | +91.0% | 69.6% | 29.6% | 21.5% | $8.38B |
| FY2025 Q4 | $24.56B | +9.1% | $2.10 | +48.9% | 67.6% | 22.8% | 20.8% | $5.47B |
| FY2026 Q1 | $24.06B | +9.9% | $2.14 | -52.9% | 66.3% | 26.6% | 21.8% | $1.47B |
| FY2026 Q2Selected | $25.31B | +6.6% | $2.27 | -0.9% | 68.2% | 28.3% | 21.9% | $3.39B |
| FY2026 Q3 | $25.40B | +5.9% | $0.09 | -96.0% | 73.0% | 25.1% | 0.8% | — |
Management’s own words, often on a non-GAAP, constant-currency, or adjusted basis — so these can differ from the GAAP figures above (e.g. constant-currency revenue growth excludes currency swings).
Calendar quarter Q2 2026Earnings call Jul 15, 2026
FY2026 Q2 in brief
Johnson & Johnson delivered a Q2 2026 beat, with worldwide sales of $25.3 billion up 5.6% operationally and management raising full-year operational sales guidance by $400 million to a 6.5%-7.1% range.
Newest quarter FY2026 Q3 is part of Pro · see what Pro adds →
Sources. Tellvest earnings-call sentiment score for Johnson & Johnson (JNJ), FY2026 Q2: 7/10. Scores: Johnson & Johnson’s public earnings-call transcripts and SEC-reported results — the base band is anchored to reported GAAP revenue growth; transcript, EPS and guidance adjustments are applied separately (documented exceptions apply to a few issuers). Price: JNJ daily closing prices for the trailing year; dots mark earnings calls, colored by that quarter’s score; the newest quarter’s score is part of Tellvest Pro. How to read a company earnings-call score.
What JNJ and other companies said about each other on FY2026 Q2 earnings calls — extracted verbatim from public transcripts. Mentions from the newest quarter are a Pro feature.
“This will be the first clinical readout from an ongoing study from our recent Ambrx acquisition.”
J&J points to an upcoming prostate-cancer data readout (J&J 6143) as the first clinical output from its Ambrx acquisition, underscoring pipeline contribution from the deal.
“A good example of that is the recently announced agreement to acquire Firefly Bio.”
GAAP revenue YoY +6.60% → base 6. The base score is anchored to the GAAP revenue YoY band before transcript, EPS, and guidance adjustments.
J&J's planned Firefly Bio acquisition, expected to close in Q3 2026, adds a platform targeting KRAS-driven solid tumors and diversifies its oncology pipeline.
“In GI, TREMFYA seems to have an edge over SKYRIZI, yet SKYRIZI is holding its own.”
An analyst frames AbbVie's SKYRIZI as a resilient IBD competitor to J&J's TREMFYA, though management counters that TREMFYA leads induction share in ulcerative colitis and Crohn's.
| Company | Score | Trend | Rev YoY |
|---|---|---|---|
JNJ Johnson & Johnson | 7 | +6.6% | |
| ABBV AbbVie | 9 | +10.2% | |
| AMGN Amgen Inc. | 9 | +9.7% | |
| BIIB Biogen | 3 | +3.4% | |
| BMY Bristol Myers Squibb | 8 | +5.7% | |
| GILD Gilead Sciences | 8 | +10.2% | |
| LLY Lilly (Eli) | 10 | +47.7% | |
| MRK Merck & Co., Inc. | 7 | +5.1% | |
| PFE Pfizer | 6 | +2.6% |